Andrew Ittleman exclusively represents clients in highly regulated industries, such as regenerative medicine and other FDA-regulated issues. Ittleman has been invited to speak at numerous conferences and panels on FDA enforcement issues, FDA regulation of stem cells and FDA regulation of off-label use. He also litigates extensively against the United States government in civil and criminal matters.